"This study is a single-center, randomized, open-label, 3-period, 5-treatment, 6-sequence
design. A total of 54 eligible subjects will receive three total treatments; one with
intravenous (IV) infusion and two with the Study System. Each subject will be randomly
assigned to receive a treatment sequence consisting of Treatment A (IV fentanyl citrate),
Study System Treatment B (170 mcAmp), and one of three additional Study System treatments
(140 mcAmp or 200 mcAmp or 230 mcAmp) "